Unlocking the Power of
Cardiac Energy Metabolism
ABOUT
Fueling the next generation of cardiovascular therapies
We are translating our deep understanding of cardiac energy metabolism into novel cardiovascular disease treatments designed to transform care for patients with limited treatment options. By enhancing or restoring the cell’s ability to produce and use energy, we aim to address a fundamental driver of cardiovascular disease.
OUR FOCUS
Developing Life-Altering Treatments for Cardiovascular Disease
Non-obstructive Hypertrophic Cardiomyopathy
Non-obstructive hypertrophic cardiomyopathy (nHCM) is a genetic heart disease that occurs when the heart muscle becomes abnormally thickened, impairing the heart’s ability to fill properly and efficiently pump blood to meet the body’s metabolic demands.
Learn more about the FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat for nHCM (NCT07023614)
LATEST NEWS
Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases
Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments
Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25
Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25)
Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024
Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
MISSION & VALUES
At Imbria Pharmaceuticals, our mission is to advance transformative cardiovascular therapeutics by targeting the heart’s energy metabolism.